Skip to main
ATXS
ATXS logo

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Astria Therapeutics Inc. is making significant strides with its product candidates STAR-0215 and STAR-0310, both of which demonstrate promising efficacy and safety profiles, particularly with STAR-0310 showing greater therapeutic potential compared to first-generation OX40 antibodies due to its well-tolerated treatment responses. The potential for STAR-0310 to improve quality of life by reducing treatment burden positions it favorably within the market, complemented by BioCryst's established commercial infrastructure, which is expected to enhance operational profitability following the anticipated launch of navenibart. With a substantial market opportunity and the strategic growth potential supported by the synergistic capabilities of the combined entities, Astria is poised for significant advancements as it continues to build its pipeline and leverage upcoming news flow.

Bears say

The financial outlook for Astria Therapeutics Inc is marked by significant risks stemming from potential failures in clinical trials, which could hinder the advancement of its product candidates, such as STAR-0215 and STAR-0310. Additionally, the company's ability to secure necessary funding for the development of its therapies remains uncertain, posing a challenge for continuous progress in their pipeline. Lastly, the removal of the price target and a downgrade to a neutral position underscore concerns regarding the overall valuation, aggravated by the threat of acquisition uncertainties and unmet clinical milestones.

Astria Therapeutics (ATXS) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 6 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.